Track market-moving stories before they get noisy

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,944,444 ADSs. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $201.3 million.

Jefferies, Morgan Stanley, Cantor and William Blair acted as joint book-running managers for the offering.

A shelf registration statement relating to the securities in the offering described above was filed with the U.S. Securities and Exchange Commission (“SEC”) on May 18, 2026, and declared effective by the SEC on May 27, 2026. The offering was made by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement, as well as a related registration statement on Form S-3MEF. A final prospectus supplement and the accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

For readers in the European Economic Area (“EEA”)

In any EEA member state (each, a “Relevant State”), this press release and any offering are only addressed to and directed at persons who are qualified investors (“Qualified Investors”) in that Relevant State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.

This press release must not be acted on or relied on in any EEA member state by persons who are not Qualified Investors. Any investment or investment activity to which this press release relates is available only to and will only be engaged with Qualified Investors in any EEA member state.

For readers in the United Kingdom

In the UK, this press release and any offering are only addressed to and directed at persons who are qualified investors (“UK Qualified Investors”) within the meaning of paragraph 15 of Part 2 of Schedule 1 of The Public Offers and Admissions to Trading Regulations 2024/105.

In the United Kingdom, this press release, in so far as it constitutes an invitation or inducement to enter into investment activity within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA”), and any offering are only addressed to and directed at UK Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the “Order”, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”).

This press release must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to and will only be engaged with relevant persons in the United Kingdom. This press release does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of the FSMA or otherwise.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.

Key Takeaways SLN completed SANRECO enrollment ahead of schedule, accelerating the top-line data to August 2026.SLN is seeking a strategic partner to advance phase III-ready zerlasiran after positive FDA and EMA feedback.Silence Therapeutics regained global rights to SLN312 after AstraZeneca ended the program's development. Shares of Silence Therapeutics (SLN - Free Report) have surged 107% over the past six months, driven by investor optimism around the company's advancing RNA interference (siRNA) pipeline, upcoming clinical data readouts and the long-term growth potential of its lead candidate, divesiran.

Divesiran: SLN’s Major Growth DriverInvestor sentiment has been fueled by the rapid clinical progress of divesiran, Silence Therapeutics’ first-in-class siRNA therapy targeting TMPRSS6 for the treatment of patients with polycythemia vera (PV), a rare myeloproliferative blood cancer characterized by excessive production of red blood cells and elevated hematocrit levels.

The ongoing phase II SANRECO study is evaluating divesiran at a 6 mg dose with every-six-week (Q6W) and every-12-week (Q12W) dosing schedules in patients with PV. The study completed patient enrollment ahead of schedule. As a result, the company accelerated the anticipated top-line data readout from the second half of 2026 to the third quarter of 2026 (August 2026). Positive study data could serve as a significant catalyst for the stock. Earlier phase I data demonstrated meaningful reductions in phlebotomy requirements, improvements in disease-related symptoms and quality of life and a favorable safety profile.

Year to date, shares of Silence Therapeutics have jumped 71.9% against the industry’s 1.5% drop.

Image Source: Zacks Investment Research

SLN’s Other Pipeline Assets on the MoveBeyond divesiran, Silence Therapeutics continues to strengthen its long-term growth outlook through a diversified RNAi pipeline. Zerlasiran (SLN360) is SLNs’ phase III-ready siRNA candidate for cardiovascular disease associated with elevated lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart attack and stroke. In phase I and phase II studies, zerlasiran demonstrated substantial and durable reductions in Lp(a) with infrequent dosing and a favorable safety profile. Following positive regulatory feedback from the FDA and EMA, and the completion of key phase III readiness activities, the company is seeking a strategic partner to advance late-stage development and commercialization of the program.

SLN312 Faces Development Setback Following AstraZeneca ExitAnother promising asset, SLN312, is an siRNA therapy targeting ANGPTL3 for the treatment of dyslipidemia. However, the candidate faced a setback in March, after its former partner, AstraZeneca (AZN - Free Report) , decided to discontinue further development of the program following a phase I study. Although the study demonstrated durable, dose-dependent reductions in ANGPTL3, triglycerides and atherogenic lipoproteins, along with a favorable safety profile and the potential for infrequent dosing, AZN chose not to advance the candidate into later-stage development. As a result, Silence Therapeutics will regain global rights to SLN312 and must now determine the program's future, either by funding its development internally or securing a new strategic partner.

SLN’s Zacks Rank & Stocks to ConsiderSilence Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.48. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 21.3% year to date.

Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have surged 125.4% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.